{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:42:27Z","timestamp":1790854947393,"version":"4.1.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.parkreldis.2006.08.005","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T03:26:03Z","timestamp":1170473163000},"page":"453-454","source":"Crossref","is-referenced-by-count":78,"title":["A pilot study of the clinical efficacy and safety of memantine for Huntington's disease"],"prefix":"10.1016","volume":"13","author":[{"given":"William G.","family":"Ondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicte I.","family":"Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2006.08.005_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Verhagen Metman","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2006.08.005_bib2","doi-asserted-by":"crossref","unstructured":"Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M. The N-methyl-d-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Supp 2004:117\u2013122.","DOI":"10.1007\/978-3-7091-0579-5_14"},{"key":"10.1016\/j.parkreldis.2006.08.005_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.febslet.2004.04.047","article-title":"Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration","volume":"566","author":"Li","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.parkreldis.2006.08.005_bib4","first-page":"91","article-title":"Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties","volume":"43","author":"Kornhuber","year":"1994","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.parkreldis.2006.08.005_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3940(03)00398-7","article-title":"Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum","volume":"343","author":"Peeters","year":"2003","journal-title":"Neurosci Lett"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380200600215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380200600215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T03:39:58Z","timestamp":1556077198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380200600215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S135380200600215X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2006.08.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}